IMARC Group has recently released a report titled “Exocrine Pancreatic Insufficiency Market: Analysis of Epidemiology, Industry Trends, Size, Share, and Future Forecast (2023-2033)” that presents a comprehensive assessment of the exocrine pancreatic insufficiency market size. The report provides an extensive overview of the latest market trends, growth prospects, investment opportunities, and industry outlook, as well as an in-depth analysis of the disease landscape, market scenario, and growth trends. Furthermore, the report offers an analysis of competitors, regional markets, and recent advancements in the market. It also sheds light on crucial segments and market drivers, along with challenges faced by industry players. This report is a valuable resource for stakeholders who want to gain valuable insights into the exocrine pancreatic insufficiency market.
Exocrine pancreatic insufficiency (EPI) refers to a chronic condition in which the pancreas fails to generate enough digestive enzymes that are necessary for the proper breakdown of food and the absorption of vital nutrients. This leads to maldigestion, a shortage of vitamins, and nutrient malabsorption from routine digestive processes. The symptoms of EPI include abdominal discomfort, belly pain, fatigue, diarrhea, bleeding disorders, foul-smelling stool, rapid weight loss, etc. The diagnosis of this condition involves a review of the medical history, a secretin stimulation test, an MRI, and a CT scan.
Request a Free Sample Report: https://www.imarcgroup.com/exocrine-pancreatic-insufficiency-market/requestsample
The rising prevalence of chronic pancreatitis, which leads to inflammation of the pancreas and affects its potential to produce digestive enzymes, is primarily driving the exocrine pancreatic insufficiency market. Furthermore, the increasing cases of inherited diseases, including cystic fibrosis, that can obstruct the pancreatic ducts and prevent the release of essential enzymes are also augmenting the market growth. Besides this, the escalating adoption of pancreatic enzyme replacement therapy to treat EPI, as it significantly improves fat digestion and manages the symptoms of the ailment, is providing a positive outlook for the market.
Moreover, the growing popularity of non-invasive techniques, such as secretin-enhanced magnetic resonance cholangiopancreatography (MRCP), to diagnose and evaluate the exocrine function and visualize improvements in the pancreatic duct is acting as another significant growth-inducing factor. Apart from this, the increasing adoption of combination treatments involving lifestyle changes, including limitation of alcohol intake, prohibition of smoking, consumption of a healthy diet, and vitamin supplementation, is expected to propel the exocrine pancreatic insufficiency market during the forecasted period.
Report Period:
- Base Year: 2022
- Historical Period: 2017-2022
- Market Forecast: 2023-2033
Countries Included:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the exocrine pancreatic insufficiency market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the exocrine pancreatic insufficiency market
- Reimbursement scenario in the market
- In-market and pipeline drugs
In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Regulatory Status
Ask an Analyst for Report Customization with TOC & List of figures: https://www.imarcgroup.com/exocrine-pancreatic-insufficiency-market
Key Questions Answered in this Report:
- How has the exocrine pancreatic insufficiency market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
- What was the country-wise size of the exocrine pancreatic insufficiency market across the seven major markets in 2022 and what will it look like in 2033?
- What is the growth rate of the exocrine pancreatic insufficiency market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Browse the Latest Research Report:
Warm Autoimmune Hemolytic Anemia (WAIHA) Market Report 2023-2033
Genital Warts Market Report 2023-2033
Frontotemporal Dementia Market Report 2023-2033
Hyperkalemia Market Report 2023-2033
About Us: –
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
